Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
PHASE1CompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
March 31, 2004
Primary Completion Date
January 31, 2005
Study Completion Date
June 30, 2005
Conditions
Renal Impairment
Interventions
DRUG
Methylnaltrexone (MNTX)
Trial Locations (1)
10591
Progenics Pharmaceuticals, Inc., Tarrytown
All Listed Sponsors
lead
Bausch Health Americas, Inc.
INDUSTRY
NCT01367509 - Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function | Biotech Hunter | Biotech Hunter